Curated News
By: NewsRamp Editorial Staff
May 20, 2026

Scinai Appoints Eilon Elmalem as CDMO Site Head for Expansion

Discuss on Substack
Original Source

TLDR

  • Scinai Immunotherapeutics appoints experienced site head to scale CDMO operations and strengthen its market position.
  • Eilon Elmalem, with 20+ years experience, will oversee site operations and engineering at Scinai Biopharma Services' Yavne CDMO facility.
  • Scinai expands its CDMO platform to help biotech companies bring innovative therapies to patients faster.
  • Scinai's new site head Eilon Elmalem previously served as an external consultant for two years before this appointment.

Impact - Why it Matters

This appointment matters because it signals Scinai’s aggressive push to scale its CDMO operations, which could attract more biotech clients seeking high-quality manufacturing services. For investors, it indicates management’s focus on operational growth and potential revenue diversification beyond its own pipeline. The move also strengthens Scinai’s position in the competitive biologics manufacturing market, offering a path to profitability and long-term value creation.

Summary

Scinai Immunotherapeutics (NASDAQ: SCNI) has announced the appointment of Eilon Elmalem as site head of its wholly owned subsidiary Scinai Biopharma Services’ Yavne CDMO facility, effective June 14, 2026. Elmalem, who has supported the company as an external consultant for the past two years, brings more than two decades of biotechnology and pharmaceutical operations experience. He will oversee site operations and engineering activities as Scinai continues expanding its contract development and manufacturing platform. This strategic hire underscores Scinai’s commitment to strengthening its CDMO capabilities and scaling its operations to meet growing demand for biologics manufacturing services.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies, with a pipeline of therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) that provides development and manufacturing services to biotechnology and pharmaceutical companies. The appointment of Elmalem is expected to enhance the operational efficiency and engineering excellence at the Yavne facility, positioning Scinai to better serve its clients and advance its own pipeline.

For investors and industry watchers, the latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI. This move reflects Scinai’s strategic focus on expanding its CDMO footprint while advancing its immunology pipeline. The company’s dual focus on innovative therapies and contract manufacturing services offers a unique value proposition in the biotech sector.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Appoints Eilon Elmalem as CDMO Site Head for Expansion

blockchain registration record for this content.